Medication Review After Clinical Deterioration: A Comprehensive Clinical Perspective

Abstract

Medication review following clinical deterioration is a critical process in modern medical practice, ensuring ongoing patient safety and optimal therapeutic outcomes. This article explores the epidemiology, underlying mechanisms, risk factors, clinical presentation, diagnostic approach, management strategies, and recent advances related to post-deterioration medication review. Emphasis is placed on evidence-based recommendations, practical implications, and the incorporation of guideline-directed care for clinicians involved in the complex task of medication management in acutely unwell patients.

Introduction

Acute clinical deterioration, whether in hospital or outpatient settings, often prompts a re-evaluation of ongoing pharmacotherapy. Medication review is essential to identify contributing factors, prevent further harm, and optimize therapy. This process is particularly relevant in multimorbid populations, where polypharmacy and drug interactions are common. Recent data underscore the importance of structured medication review post-deterioration, highlighting its role in reducing adverse drug events (ADEs), improving patient outcomes, and aligning therapy with current clinical status and goals of care.

Epidemiology / Disease Burden

Clinical deterioration remains a significant cause of morbidity and mortality, particularly among older adults and those with multiple comorbidities. Medication-related problems account for a substantial proportion of hospital admissions and in-hospital deteriorations, with estimates suggesting that up to 30% of acute hospital admissions in elderly populations are medication-related. Studies from the past decade have demonstrated that inappropriate prescribing, non-adherence, and unrecognized adverse effects are key contributors to clinical decline, underscoring the burden and necessity for routine medication reviews in this context.

Pathophysiology

The pathophysiology of medication-related clinical deterioration is multifactorial. Mechanisms include direct drug toxicity, pharmacodynamic interactions, pharmacokinetic alterations due to organ dysfunction, and cumulative effects in the setting of polypharmacy. Age-related changes in drug metabolism, impaired renal or hepatic function, and acute illness states can all precipitate or exacerbate adverse drug reactions (ADRs), leading to clinical worsening. For example, acute kidney injury may reduce the clearance of renally excreted drugs, resulting in toxicity, while acute infection or dehydration may potentiate the effects of antihypertensives or antidiabetics, leading to hypotension or hypoglycemia.

Risk Factors

Several risk factors predispose patients to medication-related deterioration. These include advanced age, multiple comorbidities, polypharmacy (typically defined as the use of five or more medications), recent changes in medication regimens, cognitive impairment, and poor health literacy. Additional factors such as transitions of care, inadequate communication between healthcare providers, and lack of regular medication reconciliation further increase risk. Recognizing these factors is crucial in identifying patients most likely to benefit from comprehensive medication review post-deterioration.

Clinical Features

Medication-related clinical deterioration can manifest with a wide spectrum of symptoms, often mimicking primary disease exacerbations. Common presentations include acute confusion or delirium, falls, hypotension, hypoglycemia, renal or hepatic dysfunction, bleeding, and new-onset arrhythmias. Non-specific symptoms, such as general malaise, anorexia, or functional decline, are particularly frequent in older adults. Importantly, these signs may be subtle, necessitating a high index of suspicion and a systematic approach to medication review when evaluating acutely deteriorating patients.

Diagnosis

Diagnosing medication-related deterioration requires a thorough clinical assessment, detailed medication history, and a structured review of current and recent pharmacotherapy, including over-the-counter and herbal supplements. Tools such as the STOPP/START criteria, Beers Criteria, and clinical decision support systems can assist in identifying potentially inappropriate medications and drug-drug interactions. Laboratory investigations should evaluate organ function (e.g., renal, hepatic, electrolytes), and, where indicated, drug levels. Multidisciplinary collaboration, involving clinical pharmacists, is increasingly recognized as a best practice in this diagnostic process.

Treatment & Management

Management begins with the immediate cessation or adjustment of suspected offending agents, alongside supportive care tailored to the clinical scenario. A systematic medication review aims to deprescribe unnecessary or harmful medications, optimize dosing, and ensure therapeutic appropriateness based on current physiological status. Communication with patients and the healthcare team is vital to ensure understanding and adherence to revised regimens. In the acute care setting, frequent monitoring is essential to detect recurrence or further deterioration. Post-discharge follow-up and ongoing medication reconciliation are crucial components of long-term management.

Recent Advances / Emerging Therapies

Recent advances include the integration of electronic clinical decision support tools, which provide real-time alerts about potential drug interactions and inappropriate prescribing, particularly in high-risk populations. Pharmacogenomic testing is emerging as a tool to personalize therapy and minimize ADRs. The adoption of multidisciplinary medication review teams, including geriatricians, clinical pharmacists, and primary care providers, has demonstrated reductions in ADEs and improved patient outcomes in multiple clinical trials. Ongoing research continues to refine risk stratification tools and develop protocols for proactive medication review in vulnerable populations.

Guideline Recommendations

Current international guidelines, including those from the National Institute for Health and Care Excellence (NICE) and the American Geriatrics Society, recommend structured medication review after any episode of clinical deterioration, particularly for older adults and those with multiple comorbidities. Key recommendations include regular medication reconciliation at all transitions of care, use of validated assessment tools, and shared decision-making with patients and families. Education and training of healthcare professionals in medication safety principles are emphasized to embed medication review as a routine clinical practice.

Conclusion

Medication review after clinical deterioration is a cornerstone of patient safety, quality care, and therapeutic optimization. Through a systematic, evidence-based approach, clinicians can identify and mitigate medication-related risks, tailor therapy to current clinical needs, and improve outcomes for vulnerable patients. Continued advances in technology, multidisciplinary collaboration, and adherence to guideline recommendations will further enhance the effectiveness of medication review processes, reinforcing their essential role in modern healthcare delivery.